The AAPM 2021 educational program will be available in fall 2020. In the meantime browse 2020 meeting sessions and speakers to get a sense of the premier pain education offered during the AAPM Annual Meeting & Preconferences. Access recordings of past meeting sessions on demand.

AJOVY® (fremanezumab-vfrm) Injection: An anti-CGRP for the Preventive Treatment of Migraine in Adults

Faculty

Charles E. Argoff , MD, CPE
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, NY

Educational Objectives

After attending this symposium, participants should be better able to:

  • Provide a review of migraine impact, diagnosis, and treatment guidelines
  • Review recent information on migraine pathophysiology and the role of CGRP in ­migraine
  • Discuss clinical trial study design and background on AJOVY as an anti-CGRP for the preventive treatment of migraine in adults
  • Review the efficacy, safety, and dosing/ administration of AJOVY in clinical trials

Description

During this presentation, faculty will provide an overview of AJOVY® (fremanezumab-vfrm) injection as a preventive treatment of migraine in adults. The presentation will begin with a discussion of the migraine disease state, including migraine pathophysiology. This will be followed by a review of the efficacy and safety of AJOVY. Additionally, participants will have the opportunity to ask questions of the faculty.

IMPORTANT SAFETY_INFORMATION (continued)

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions (_5% and greater than placebo) were injection site reactions.

Activity sponsored by: Teva Pharmaceuticals